2021年3月3日 · Bardoxolone is an investigational, once-daily, orally administered activator of Nrf2 in development for the treatment of Alport syndrome and autosomal dominant polycystic …

Bardoxolone methyl (also known as “RTA 402”, “CDDO-methyl ester”, CDDO-Me, and more formally methyl bardoxolonate) is an experimental and orally-bioavailable semi-synthetic …

2016年10月20日 · Bardoxolone, a synthetic triterpenoid, is a highly potent activator of redox-sensitive signaling pathways that induce programmed cell death (apoptosis) in cancer cells …

2021年12月8日 · • Do bardoxolone methyl’s effects on albuminuria, blood pressure or other parameters raise concerns about its long-term efficacy and/or safety in patients with Alport …

Medscape - Chronic kidney disease caused by Alport syndrome dosing for bardoxolone, frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & …

Bardoxolone methyl, the C-28 methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO) known as CDDO-Me or RTA 402, is one of the derivatives of synthetic triterpenoids. …

Bardoxolone is an orally available semi-synthetic triterpenoid with the scaffold structure found in the natural product oleanolic acid. New pre-clinical studies indicate that the compound …

Bardoxolone is a novel drug that is a robust inducer of the Nrf2 pathway, which inhibits NF- κ B, leading to antioxidant and anti-inflammatory effects (1). It was initially developed as a …

A synthetic triterpenoid compound with potential antineoplastic and anti-inflammatory activities. Bardoxolone blocks the synthesis of inducible nitric oxide synthase (iNOS) and inducible …

Bardoxolone, a synthetic triterpenoid, is a highly potent activator of redox-sensitive signaling pathways that induce programmed cell death (apoptosis) in cancer cells that are under high …